Catalog No.
DHD82301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
IGFBP8, IGF-binding protein 8, IBP-8, CTGF, HCS24, CCN family member 2, CCN2, Cellular communication network factor 2, Hypertrophic chondrocyte-specific protein 24, Connective tissue growth factor, Insulin-like growth factor-binding protein 8, IGFBP-8
Concentration
4.35mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P29279
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
FG-3019, CAS: 946415-13-0
Clone ID
Pamrevlumab
[Diabetic nephropathy: emerging treatments], PMID: 24938412
Antibodies to watch in 2020, PMID: 31847708
Antibody-based therapies for idiopathic pulmonary fibrosis, PMID: 32098521
Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis, PMID: 28610597
Anti-connective tissue growth factor antibody treatment reduces extracellular matrix production in trabecular meshwork and lamina cribrosa cells, PMID: 24204045
Blocking CTGF/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury, PMID: 32227398
Blocking CTGF/CCN2 reverses neural fibrosis and sensorimotor declines in a rat model of overuse-induced median mononeuropathy, PMID: 32379362
Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis, PMID: 31811619
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer, PMID: 26575166
Connective Tissue Growth Factor Is a Novel Prodepressant, PMID: 29861095
Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model, PMID: 29719620
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer, PMID: 23836645
CTGF is a therapeutic target for metastatic melanoma, PMID: 23435419
Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β, PMID: 30716392
Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis, PMID: 28376190
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis, PMID: 26965296
FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition, PMID: 27059922
Focal segmental glomerulosclerosis: molecular genetics and targeted therapies, PMID: 26156092
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer, PMID: 32817130
Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis, PMID: 28710437
Molecular targets for treatment of kidney fibrosis, PMID: 23179685
Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011, PMID: 21386633
Novel agents in the treatment of pancreatic adenocarcinoma, PMID: 23474556
Novel therapies for diabetic kidney disease, PMID: 24602462
Onkologie und Versorgung in Fach- und Publikumsmedien: Antikörper Pamrevlumab bei radiogen induzierter Lungenfibrose? L-Carnitin und Omega-3-Fettsäuren zur Verhinderung von Kardiotoxizität durch Anthrazykline? Krebsrisiko bei Nachkommen nach Kinderwunschbehandlung? Tumormarker CA 50 beim Pankreaskarzinom – noch relevant? Immunschwäche nach Krebstherapie?, PMID: 33173255
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis, PMID: 32447983
Pamrevlumab in idiopathic pulmonary fibrosis, PMID: 31575507
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial, PMID: 31575509
Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria, PMID: 20522536
Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity, PMID: 30400950
Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab, PMID: 29347981
Surgical strategies and novel therapies for locally advanced pancreatic cancer, PMID: 28513899
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis, PMID: 33054319
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth, PMID: 24154679
Treatment of Renal Fibrosis-Turning Challenges into Opportunities, PMID: 28284377
Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment. [DHD82301]
For research use only. Not for human or drug use.
